Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Survey on Quantitative Claims in Direct-to-Consumer Prescription Drug Advertising, 59742 [2024-16096]
Download as PDF
59742
Federal Register / Vol. 89, No. 141 / Tuesday, July 23, 2024 / Notices
information. The previously approved
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (PRA) (44 U.S.C.
3501–3521). The collections of
information in 21 CFR 201.56 and
201.57 pertaining to prescription
product labeling requirements have
been approved under OMB control
number 0910–0572; the collections of
information in 21 CFR parts 210 and
211 pertaining to current good
manufacturing practice have been
approved under OMB control number
0910–0139; the collections of
information in section 351(k) of the PHS
Act pertaining to biosimilar and
interchangeable biosimilar product
applications have been approved under
OMB control number 0910–0718; and
the collections of information in section
351 of the PHS Act and 21 CFR part 601
have been approved under OMB control
number 0910–0338.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
vaccines-blood-biologics/guidancecompliance-regulatory-informationbiologics/biologics-guidances, https://
www.fda.gov/regulatory-information/
search-fda-guidance-documents, or
https://www.regulations.gov.
Dated: July 16, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
the Paperwork Reduction Act of 1995
(PRA).
FOR FURTHER INFORMATION CONTACT:
Amber Sanford, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–8867, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
December 21, 2023, the Agency
submitted a proposed collection of
information entitled ‘‘Survey on
Quantitative Claims in Direct-toConsumer Prescription Drug
Advertising’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0929. The
approval expires on June 30, 2027. A
copy of the supporting statement for this
information collection is available on
the internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: July 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–16096 Filed 7–22–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[FR Doc. 2024–16128 Filed 7–22–24; 8:45 am]
[Docket No. FDA–2024–N–2931]
BILLING CODE 4164–01–P
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Microbiological
Testing and Corrective Measures for
Bottled Water
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
AGENCY:
[Docket No. FDA–2023–N–0795]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Survey on Quantitative Claims in
Direct-to-Consumer Prescription Drug
Advertising
AGENCY:
Food and Drug Administration,
ddrumheller on DSK120RN23PROD with NOTICES1
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing that a collection of
information entitled ‘‘Electronic
Records: Electronic Signatures’’ has
been approved by the Office of
Management and Budget (OMB) under
SUMMARY:
VerDate Sep<11>2014
18:47 Jul 22, 2024
Jkt 262001
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the procedure by
which both domestic and foreign bottled
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
water manufacturers that sell bottled
water in the United States maintain
records of microbiological testing and
corrective measures, in addition to
existing recordkeeping requirements.
DATES: Either electronic or written
comments on the collection of
information must be submitted by
September 23, 2024.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
September 23, 2024. Comments received
by mail/hand delivery/courier (for
written/paper submissions) will be
considered timely if they are received
on or before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
E:\FR\FM\23JYN1.SGM
23JYN1
Agencies
[Federal Register Volume 89, Number 141 (Tuesday, July 23, 2024)]
[Notices]
[Page 59742]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-0795]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Survey on Quantitative Claims in
Direct-to-Consumer Prescription Drug Advertising
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
that a collection of information entitled ``Electronic Records:
Electronic Signatures'' has been approved by the Office of Management
and Budget (OMB) under the Paperwork Reduction Act of 1995 (PRA).
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
[email protected].
SUPPLEMENTARY INFORMATION: On December 21, 2023, the Agency submitted a
proposed collection of information entitled ``Survey on Quantitative
Claims in Direct-to-Consumer Prescription Drug Advertising'' to OMB for
review and clearance under 44 U.S.C. 3507. An Agency may not conduct or
sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB control number.
OMB has now approved the information collection and has assigned OMB
control number 0910-0929. The approval expires on June 30, 2027. A copy
of the supporting statement for this information collection is
available on the internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: July 17, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-16096 Filed 7-22-24; 8:45 am]
BILLING CODE 4164-01-P